KEYTRUDA ® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Dateline City:
KENILWORTH, N.J. First Presentation of Patient-Reported Outcomes from KEYNOTE-024 Study of Patients with Metastatic NSCLC Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) Findings Presented in Plenary Session at 17 th World Conference on Lung CancerKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced positive health-related quality of life (HRQoL) findings
from an exploratory analysis from the phase 3 KEYNOTE-024 study
investigating the use of KEYTRUDA® (pembrolizumab), the
company ’s anti-PD-1 therapy, compared to standard of care (SOC)
platinum-containing chemotherapy for the treatment of patients with
metastatic non-small cell lung cancer (NSCLC) whose tumors express high
levels of PD-L1 (tumor proportion score [TPS] ofLanguage:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK KETYRUDA MSD NSCLC NYSE:MRK Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Conferences | Drugs & Pharmacology | Lung Cancer | Merck | Non-Small Cell Lung Cancer | Study